See more : Hank Payments Corp. (HANK.V) Income Statement Analysis – Financial Results
Complete financial analysis of Sunny Pharmtech Inc. (6676.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sunny Pharmtech Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Royal Caribbean Cruises Ltd. (RCL) Income Statement Analysis – Financial Results
- Zogenix, Inc. (0M3O.L) Income Statement Analysis – Financial Results
- Cera Sanitaryware Limited (CERA.BO) Income Statement Analysis – Financial Results
- Seigakusha Co.,Ltd. (2179.T) Income Statement Analysis – Financial Results
- Investimentos Bemge S.A. (FIGE3.SA) Income Statement Analysis – Financial Results
Sunny Pharmtech Inc. (6676.TWO)
About Sunny Pharmtech Inc.
Sunny Pharmtech Inc. engages in the research, development, production, and sale of drug substances and products, and active pharmaceutical ingredients in Taiwan and internationally. Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; aminocaproic acid tablets for blood diseases, as well as for hyper-proteolytic enzymes; and carboprost tromethamine injection for therapeutic abortion and postpartum hemorrhage. The company was founded in 1994 and is based in Taoyuan, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 428.83M | 359.59M | 241.00M | 419.94M | 234.48M |
| Cost of Revenue | 143.30M | 152.88M | 125.25M | 195.87M | 139.23M |
| Gross Profit | 285.53M | 206.71M | 115.75M | 224.07M | 95.25M |
| Gross Profit Ratio | 66.58% | 57.48% | 48.03% | 53.36% | 40.62% |
| Research & Development | 208.87M | 255.88M | 171.37M | 182.04M | 205.65M |
| General & Administrative | 115.93M | 115.25M | 98.76M | 89.20M | 86.90M |
| Selling & Marketing | 32.82M | 23.20M | 21.62M | 27.17M | 16.74M |
| SG&A | 148.76M | 138.45M | 120.39M | 116.37M | 103.64M |
| Other Expenses | 0.00 | 20.59M | 6.47M | -22.11M | 0.00 |
| Operating Expenses | 357.62M | 394.33M | 291.75M | 298.41M | 314.28M |
| Cost & Expenses | 500.92M | 547.21M | 417.00M | 494.28M | 453.51M |
| Interest Income | 5.73M | 1.38M | 361.00K | 1.48M | 1.01M |
| Interest Expense | 11.24M | 4.59M | 5.62M | 6.80M | 8.28M |
| Depreciation & Amortization | 121.22M | 111.70M | 104.86M | 105.62M | 93.17M |
| EBITDA | 69.14M | -53.96M | -64.31M | 10.66M | -119.65M |
| EBITDA Ratio | 16.12% | -15.01% | -26.69% | 2.54% | -51.55% |
| Operating Income | -72.10M | -165.65M | -169.17M | -94.97M | -214.04M |
| Operating Income Ratio | -16.81% | -46.07% | -70.20% | -22.61% | -91.28% |
| Total Other Income/Expenses | 8.78M | 17.38M | 1.21M | -27.42M | -12.26M |
| Income Before Tax | -63.32M | -170.24M | -174.79M | -101.76M | -226.30M |
| Income Before Tax Ratio | -14.77% | -47.34% | -72.53% | -24.23% | -96.51% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -63.32M | -170.24M | -174.79M | -101.76M | -226.30M |
| Net Income Ratio | -14.77% | -47.34% | -72.53% | -24.23% | -96.51% |
| EPS | -0.44 | -1.23 | -1.28 | -0.77 | -1.76 |
| EPS Diluted | -0.44 | -1.23 | -1.28 | -0.77 | -1.76 |
| Weighted Avg Shares Out | 142.74M | 138.53M | 136.49M | 131.49M | 128.67M |
| Weighted Avg Shares Out (Dil) | 142.74M | 138.53M | 136.49M | 131.49M | 128.67M |
Source: https://incomestatements.info
Category: Stock Reports